Comprehensive Stock Comparison
Compare XOMA Corporation (XOMAP) vs XOMA Royalty Corp. (XOMA) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  XOMAP | 498.7% revenue growth vs XOMA's 498.7% |
| Value |  XOMA | Lower P/E (38.3x vs 39.1x) |
| Quality / Margins | XOMAP | 46.1% net margin vs XOMA's 41.1% |
| Stability / Safety | XOMAP | Beta 0.13 vs XOMA's 0.82 |
| Dividends | XOMA | 1.8% yield, vs XOMAP's 1.8% |
| Momentum (1Y) | XOMA | +21.7% vs XOMAP's +9.2% |
| Efficiency (ROA) | XOMAP | 8.3% ROA vs XOMA's 7.3%, ROIC -37.6% vs -37.6% |
Who Each Stock Is For
Income & stability
XOMAPDividend streak 0 yrs, beta 0.13, yield 1.8%
Growth exposure
XOMAPRev growth 498.7%, EPS growth 59.2%, 3Y rev CAGR -9.3%
Long-term compounding (10Y)
XOMA55.7% 10Y total return vs XOMAP's 51.6%
Sleep-well-at-night portfolio
XOMAPLower volatility, beta 0.13, current ratio 5.15x
Defensive / Recession hedge
XOMAPBeta 0.13, yield 1.8%, current ratio 5.15x
Business Model
What each company does and how it makes money
XOMA Corporation is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets — with no single asset dominating its income stream. The company's moat lies in its specialized expertise in evaluating and structuring royalty agreements for complex biotech assets, creating a diversified portfolio of potential future revenue streams.
XOMA Royalty Corp is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets—typically earning a percentage of future drug sales if the therapies succeed. The company's moat lies in its specialized expertise in evaluating clinical-stage assets and structuring royalty agreements that provide diversified exposure to potential blockbuster drugs without bearing development costs.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
XOMAP 3XOMA 3XOMA2/3 metricsXOMA3/4 metricsXOMAP3/3 metricsXOMAP4/6 metricsXOMAP2/2 metricsXOMA1/1 metricsXOMA leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). XOMAP leads in 3 (Profitability & Efficiency, Total Returns).
Financial Metrics (TTM)
XOMAP and XOMA operate at a comparable scale, with $47M and $47M in trailing revenue. XOMAP is the more profitable business, keeping 46.1% of every revenue dollar as net income compared to XOMA's 41.1%.
| Metric | XOMAPXOMA Corporation | XOMAXOMA Royalty Corp. |
|---|---|---|
| RevenueTrailing 12 months | $47M | $47M |
| EBITDAEarnings before interest/tax | $13M | $22M |
| Net IncomeAfter-tax profit | $22M | $19M |
| Free Cash FlowCash after capex | $5M | $5M |
| Gross MarginGross profit ÷ Revenue | +93.6% | +93.8% |
| Operating MarginEBIT ÷ Revenue | -15.0% | +4.1% |
| Net MarginNet income ÷ Revenue | +46.1% | +41.1% |
| FCF MarginFCF ÷ Revenue | +11.4% | +11.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.9% | +29.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +144.0% | +144.0% |
Valuation Metrics
| Metric | XOMAPXOMA Corporation | XOMAXOMA Royalty Corp. |
|---|---|---|
| Market CapShares × price | $321M | $305M |
| Enterprise ValueMkt cap + debt − cash | $338M | $323M |
| Trailing P/EPrice ÷ TTM EPS | -15.79x | -15.48x |
| Forward P/EPrice ÷ next-FY EPS est. | 39.12x | 38.35x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 11.26x | 10.72x |
| Price / BookPrice ÷ Book value/share | 3.72x | 3.65x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
XOMAP delivers a 20.1% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $18 for XOMA. XOMAP carries lower financial leverage with a 1.46x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMA's 1.46x.
| Metric | XOMAPXOMA Corporation | XOMAXOMA Royalty Corp. |
|---|---|---|
| ROE (TTM)Return on equity | +20.1% | +17.9% |
| ROA (TTM)Return on assets | +8.3% | +7.3% |
| ROICReturn on invested capital | -37.6% | -37.6% |
| ROCEReturn on capital employed | -19.4% | -19.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 1.46x | 1.46x |
| Net DebtTotal debt minus cash | $18M | $18M |
| Cash & Equiv.Liquid assets | $102M | $102M |
| Total DebtShort + long-term debt | $119M | $119M |
| Interest CoverageEBIT ÷ Interest expense | 2.20x | 0.67x |
Total Returns (with DRIP)
A $10,000 investment in XOMAP five years ago would be worth $14,545 today (with dividends reinvested), compared to $7,225 for XOMA. Over the past 12 months, XOMA leads with a +21.7% total return vs XOMAP's +9.2%. The 3-year compound annual growth rate (CAGR) favors XOMAP at 9.2% vs XOMA's 6.2% — a key indicator of consistent wealth creation.
| Metric | XOMAPXOMA Corporation | XOMAXOMA Royalty Corp. |
|---|---|---|
| YTD ReturnYear-to-date | -1.9% | -8.8% |
| 1-Year ReturnPast 12 months | +9.2% | +21.7% |
| 3-Year ReturnCumulative with dividends | +30.2% | +19.7% |
| 5-Year ReturnCumulative with dividends | +45.4% | -27.8% |
| 10-Year ReturnCumulative with dividends | +51.6% | +55.7% |
| CAGR (3Y)Annualised 3-year return | +9.2% | +6.2% |
Risk & Volatility
XOMAP is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than XOMA's 0.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XOMAP currently trades 86.9% from its 52-week high vs XOMA's 64.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XOMAPXOMA Corporation | XOMAXOMA Royalty Corp. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.13x | 0.82x |
| 52-Week HighHighest price in past year | $30.00 | $39.92 |
| 52-Week LowLowest price in past year | $24.96 | $18.35 |
| % of 52W HighCurrent price vs 52-week peak | +86.9% | +64.0% |
| RSI (14)Momentum oscillator 0–100 | 42.2 | 49.2 |
| Avg Volume (50D)Average daily shares traded | 778 | 478K |
Analyst Outlook
Wall Street rates XOMAP as "Buy" and XOMA as "Buy". For income investors, XOMA offers the higher dividend yield at 1.83% vs XOMAP's 1.79%.
| Metric | XOMAPXOMA Corporation | XOMAXOMA Royalty Corp. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $68.25 |
| # AnalystsCovering analysts | 9 | 10 |
| Dividend YieldAnnual dividend ÷ price | +1.8% | +1.8% |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | $0.47 | $0.47 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | +0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Dec 20 | Mar 26 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | 100 | 106.74 | +6.7% |
| XOMA Royalty Corp. (XOMA) | 100 | 64.14 | -35.9% |
XOMA Corporation (XOMAP) returned +45% over 5 years vs XOMA Royalty Corp. (XOMA)'s -28%. A $10,000 investment in XOMAP 5 years ago would be worth $14,545 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | $55M | $28M | -48.6% |
| XOMA Royalty Corp. (XOMA) | $55M | $28M | -48.6% |
XOMA Corporation's revenue grew from $55M (2015) to $28M (2024) — a -7.1% CAGR. XOMA Royalty Corp.'s revenue grew from $55M (2015) to $28M (2024) — a -7.1% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | -37.2% | -48.5% | -30.6% |
| XOMA Royalty Corp. (XOMA) | -37.2% | -48.5% | -30.6% |
XOMA Corporation's net margin went from -37% (2015) to -49% (2024). XOMA Royalty Corp.'s net margin went from -37% (2015) to -49% (2024).
Chart 4P/E Ratio History — 3 Years
| Stock | 2017 | 2021 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | 48.8 | 32.1 | -34.2% |
XOMA Royalty Corp. has traded in a 32x–57x P/E range over 3 years; current trailing P/E is ~-15x.
Chart 5EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | -1.82 | -1.65 | +9.3% |
| XOMA Royalty Corp. (XOMA) | -3.5 | -1.65 | +52.9% |
XOMA Corporation's EPS grew from $-1.82 (2015) to $-1.65 (2024). XOMA Royalty Corp.'s EPS grew from $-3.50 (2015) to $-1.65 (2024).
Chart 6Free Cash Flow — 5 Years
XOMA Corporation generated $-14M FCF in 2024 (-260% vs 2021). XOMA Royalty Corp. generated $-14M FCF in 2024 (-260% vs 2021).
XOMAP vs XOMA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is XOMAP or XOMA a better buy right now?
Analysts rate XOMA Corporation (XOMAP) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XOMAP or XOMA?
Over the past 5 years, XOMA Corporation (XOMAP) delivered a total return of +45.4%, compared to -27.8% for XOMA Royalty Corp. (XOMA). A $10,000 investment in XOMAP five years ago would be worth approximately $15K today (assuming dividends reinvested). Over 10 years, the gap is even starker: XOMA returned +55.7% versus XOMAP's +51.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XOMAP or XOMA?
By beta (market sensitivity over 5 years), XOMA Corporation (XOMAP) is the lower-risk stock at 0.13β versus XOMA Royalty Corp.'s 0.82β — meaning XOMA is approximately 515% more volatile than XOMAP relative to the S&P 500. On balance sheet safety, XOMA Corporation (XOMAP) carries a lower debt/equity ratio of 146% versus 146% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.
04Which has better profit margins — XOMAP or XOMA?
XOMA Corporation (XOMAP) is the more profitable company, earning -48.5% net margin versus -48.5% for XOMA Royalty Corp. — meaning it keeps -48.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XOMAP leads at -140.3% versus -140.3% for XOMA. At the gross margin level — before operating expenses — XOMAP leads at 99.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is XOMAP or XOMA more undervalued right now?
On forward earnings alone, XOMA Royalty Corp. (XOMA) trades at 38.3x forward P/E versus 39.1x for XOMA Corporation — 0.8x cheaper on a one-year earnings basis.
06Which pays a better dividend — XOMAP or XOMA?
All stocks in this comparison pay dividends. XOMA Royalty Corp. (XOMA) offers the highest yield at 1.8%, versus 1.8% for XOMA Corporation (XOMAP).
07Is XOMAP or XOMA better for a retirement portfolio?
For long-horizon retirement investors, XOMA Corporation (XOMAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.13), 1.8% yield). Both have compounded well over 10 years (XOMAP: +51.6%, XOMA: +55.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between XOMAP and XOMA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.